GlassScriptPhysician profile
Jitesh K Kar
NPI 1184974800
$18,141.93
in general payments reported to CMS, 2019-2025
66 companies · $3,637 in 2025
The $3,637 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $1,049 · 2021: $3,033 · 2022: $3,058 · 2023: $3,216 · 2024: $3,516 · 2025: $3,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $35.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,334.00 |
| Education | $35.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,193.61 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Abbvie INC. | $1,551.46 | 2019-2025 | |
| Pfizer INC. | $1,492.16 | 2021-2025 | |
| Lilly USA, LLC | $728.75 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Csl Behring | $721.69 | 2022-2025 | Hizentra |
| Eisai INC. | $697.76 | 2019-2025 | |
| Argenx US, INC. | $678.63 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $677.98 | 2021-2025 | |
| Amgen INC. | $656.56 | 2019-2025 | Uplizna |
| Neurelis, INC. | $497.60 | 2022-2025 | Valtoco |
| Acorda Therapeutics, INC | $473.17 | 2019-2024 | Inbrija, Ampyra |
| Allergan, INC. | $458.80 | 2020 | |
| Avanir Pharmaceuticals, INC. | $457.36 | 2019-2022 | |
| Lundbeck LLC | $444.79 | 2019-2025 | Vyepti, Rexulti |
| Neurocrine Biosciences, INC. | $414.69 | 2022-2025 | Ingrezza, Ongentys |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jitesh Kar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.